- Abzena expands quality control (QC) testing capabilities at its San Diego, CA site.
Abzena, a contract development and manufacturing organisation (CDMO) specialising in complex biologics and bioconjugates, has announced an expansion of its quality control (QC) testing capacity at its San Diego, California manufacturing site. This new laboratory aims to enhance testing services, specifically microbiology release testing, for antibody and biopharmaceutical customers, supporting the growing regulatory and market demand for quality in the sector.
The dedicated QC microbiology lab will operate as a standalone facility, separating microbiological product testing from other types of testing. This separation aligns with regulatory standards and minimises cross-contamination risks, allowing Abzena to improve scalability for high volumes of clinical material testing. Additionally, the lab design enables enhanced production capacity, with anticipated yields reaching up to 99%.
“This expansion enhances our ability to provide state-of-the-art analytical services that continue to drive progress in testing and report development for our customers,” said Sean O’Brien, SVP and San Diego Site Head at Abzena. “We look forward to working with our customers and partners to advance the frontiers of medical knowledge and provide the highest-quality testing services.”
The expanded facility is designed to accommodate additional equipment, including a new biological safety cabinet (BSC) and incubators, which will allow for future growth. Troy Wright, SVP and Global Head of Quality at Abzena, remarked, “This expansion provides even greater sample integrity in our microbiological testing capabilities. We are now positioned to deliver faster results and better support for our customer network.”
Overview of outsourcing trends 
